Lucentis® (ranibizumab)

Humana

Pharmacy Coverage Policy

Effective Date: January 01, 2022
Revision Date: April 26, 2023
Review Date: April 19, 2023
Line of Business: Medicare, Commercial, Medicaid - Kentucky, Medicaid - South Carolina, Medicaid - Ohio
Policy Type: Prior Authorization

Products Affected

Lucentis intravitreal solution for injection
Lucentis intravitreal syringe

Listed Indications

Neovascular (Wet) Age-Related Exudative Macular Degeneration (AMD)

Does the member meet all of the following criteria?	
Criteria #1	Diagnosed with neovascular (wet) age-related macular degeneration
Criteria #2	? Has a contraindication, or intolerance to bevacizumab.* OR ? Has had prior therapy with bevacizumab* and provider attests that the member has NOT demonstrated a positive clinical response to bevacizumab (e.g., improvement or maintenance in best corrected visual acuity [BCVA] or visual field, or a reduction in the rate of vision decline or the risk of more severe vision loss) *For Medicare Part B requests, the step therapy requirement does not apply if the request is a continuation of prior therapy within the past 365 days
Approval Duration	
Initial	Lucentis will be approved in plan year durations or as determined through clinical review.

Back to top

Diabetic Macular Edema (DME)

Does the member meet all of the following criteria?	
Criteria #1	Diagnosed with Diabetic Macular Edema
Criteria #2	? Has a contraindication, or intolerance to bevacizumab.* OR ? Has had prior therapy with bevacizumab* and provider attests that the member has NOT demonstrated a positive clinical response to bevacizumab (e.g., improvement or maintenance in best corrected visual acuity [BCVA] or visual field, or a reduction in the rate of vision decline or the risk of more severe vision loss) *For Medicare Part B requests, the step therapy requirement does not apply if the request is a continuation of prior therapy within the past 365 days
Approval Duration	
Initial	Lucentis will be approved in plan year durations or as determined through clinical review.

Back to top

Diabetic Retinopathy

Does the member meet all of the following criteria?	
Criteria #1	Diagnosed with Diabetic Retinopathy
Criteria #2	? Has a contraindication, or intolerance to bevacizumab.* OR ? Has had prior therapy with bevacizumab* and provider attests that the member has NOT demonstrated a positive clinical response to bevacizumab (e.g.,

	improvement or maintenance in best corrected visual acuity [BCVA] or visual field, or a reduction in the rate of vision decline or the risk of more severe vision loss) *For Medicare Part B requests, the step therapy requirement does not apply if the request is a continuation of prior therapy within the past 365 days
Approval Duration	
Initial	Lucentis will be approved in plan year durations or as determined through clinical review.

Back to top

Macular Edema Following Retinal Vein Occlusion (RVO)

Does the member meet all of the following criteria?	
Criteria #1	Diagnosed with macular edema following Retinal Vein Occlusion
Criteria #2	? Has a contraindication, or intolerance to bevacizumab.* OR ? Has had prior therapy with bevacizumab* and provider attests that the member has NOT demonstrated a positive clinical response to bevacizumab (e.g., improvement or maintenance in best corrected visual acuity [BCVA] or visual field, or a reduction in the rate of vision decline or the risk of more severe vision loss) *For Medicare Part B requests, the step therapy requirement does not apply if the request is a continuation of prior therapy within the past 365 days
Approval Duration	
Initial	Lucentis will be approved in plan year durations or as determined through clinical review.

Back to top

Myopic Choroidal Neovascularization (mCNV)

Does the member meet all of the following criteria?	
Criteria #1	Diagnosed with Myopic Choroidal Neovascularization (mCNV)
Criteria #2	? Has a contraindication, or intolerance to bevacizumab.* OR ? Has had prior therapy with bevacizumab* and provider attests that the member has NOT demonstrated a positive clinical response to bevacizumab (e.g., improvement or maintenance in best corrected visual acuity [BCVA] or visual field, or a reduction in the rate of vision decline or the risk of more severe vision loss) *For Medicare Part B requests, the step therapy requirement does not apply if the request is a continuation of prior therapy within the past 365 days
Approval Duration	
Initial	Lucentis will be approved in plan year durations or as determined through clinical review.

Back to top

Background

This is a prior authorization policy about Lucentis (ranibizumab).

Lucentis (ranibizumab) is contraindicated in patients with ocular or periocular infections.

Lucentis (ranibizumab) should not be used concurrently with other VEGF inhibitors for intraocular use in the absence of documentation indicating that individual products are to be used in different eyes.

VEGF is a naturally occurring substance in the body responsible for the growth of new blood vessels (neovascularization). In the retina however, VEGF may stimulate growth of abnormally fragile vessels prone to leakage. This leakage causes scarring in the macula and eventually leads to loss of central vision.

Age-related macular degeneration (AMD) is a major cause of painless central vision loss and is a leading cause of blindness in people over 60.

AMD occurs in two forms: dry and wet.

- Dry AMD is associated with atrophic cell death of the central retina or macula, which is required for fine vision used for activities such as reading, driving or recognizing faces. Approximately 10-20% of patients with dry AMD eventually progress to wet AMD.
- Wet AMD is associated with growth of abnormal blood vessels under the macula. These new blood vessels tend to be very fragile and often leak blood and fluid and cause scar tissue that destroys the central retina. The blood and fluid raise the macula from its normal place at the back of the eye.Damage to the macula occurs rapidly and results in a deterioration of sight over a period of months to years. Between 80% to 90% of AMD is dry, yet more than 80% of the visual loss attributable to AMD is caused by the wet form.
  The natural history of AMD is variable, with clinical manifestations dependent on disease type, extent, and whether one or both eyes are affected. Principle risk factors include age, smoking, family history, Caucasian ethnicity, contralateral eye disease, diabetes, and cataract surgery. Genetics play a particularly strong role, with a single polymorphism estimated responsible for as much as 43% of disease occurrence.
  Central retinal vein occlusion (CRVO) is a common retinal vascular disorder. The exact etiology is un known, however may be caused by arteriosclerotic changes in the central retinal artery or from a thrombotic occlusion of the central retinal vein. Occlusion of the central retinal vein leads to backup of the blood in the retinal venous system and increases resistance to the venous blood flow. This increased resistance causes stagnation of the blood and ischemia to the retina. Ischemic damage to the retina stimulates increase production of vascular endothelial growth factor (VEGF), and increased levels of VEGF stimulate neovascularization of the posterior and anterior segment of the eye.
  Treatment of CRVO includes aspirin, anti-inflammatory agents, isovolemic hemodilution, plasmapheresis, systemic anticoagulation, fibrinolytic agents, systemic corticosteroids, local anticoagulation with intravitreal injections of alteplase, intravitreal injections of triamcinolone, intravitreal injections of bevacizumab.
  There are two types of CRVO; ischemic and nonischemic.
- Nonischemic CRVO is the milder form of the disease and presents with good vision, few retinal hemorrhages and cotton-wool spots, and good perfusion to the retina. This type may resolve fully with good visual outcome or may progress to the ischemic type.
- Ischemic CRVO is the more severe form and presents with severe visual loss, extensive retinal hemorrhages, and cotton-wool spots. Poor perfusion of the retinal and patients may end up with neovascular glaucoma and painful blind eye.

In Branched retinal vein occlusion (BRVO) the blockage occurs in a smaller branch of the vessels that connect to the central retinal vein.

Both types of Retinal Vein Occlusion can lead to Macular Edema or growth of fragile new blood vessels.

Diabetic Macular Edema (DME) is the consequence of retinal microvascular changes from poorly controlled diabetes and diabetic retinopathy. DME is associated with thickening of the basement membrane and reduction of pericytes which are believed to increase permeability of the retinal vasculature. This compromises the blood-retinal barrier causing a leakage of plasma constituents and subsequent retinal edema and hypoxia, all of which stimulates the production of vascular endothelial growth factor (VEGF). DME damages the central retina, which impairs color and pinpoint vision, leading to blurry, washed-out vision. DME can be classified as either focal or diffuse types. In both cases, the predominant labeled treatment for DME is macular focal/grid laser photocoagulation (cauterization of ocular blood vessels). Intravitreal steroids and anti-VEGF agents are also used off-label. (Non-diabetic causes of macular edema include: AMD, uveitis, RVO, and certain genetic disorders.) Lucentis is the first anti-VEGF agent approved for treating DME.

Lucentis (ranibizumab) is a recombinant monoclonal antibody, ophthalmic Vascular Endothelial Growth Factor (VEGF) Inhibitor.

Lucentis (ranibizumab) binds to and inhibits vascular endothelial growth factor (VEGF-A) from promoting growth of new blood vessels beneath the

retina, by intravitreal injection.

Ranibizumab is indicated for the treatment of Exudative (wet) Age-related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), Diabetic Retinopathy, and Myopic Choroidal Neovascularization (mCNV).

Ranibizumab is available as Lucentis:

- Single-use prefilled syringe designed to provide 0.05 mL for intravitreal injection
  - 10 mg/mL solution (Lucentis 0.5 mg)
  - 0.3 mg/0.05mL solution (Lucentis 0.3mg)
- Single-use glass vial designed to provide 0.05 mL for intravitreal injections
  - 10 mg/mL solution (Lucentis 0.5 mg)
  - 6 mg/mL solution (Lucentis 0.3 mg)

Provider Claim Codes

For medically billed requests, please visit www.humana.com/PAL. Select applicable Preauthorization and Notification List(s) for medical and procedural coding information.

Medical Terms

Lucentis; ranibizumab; Neovascular (wet) Age Related Macular Degeneration; AMD; Intravitreal; Macular Edema, Retinal Vein Occlusion; RVO; Diabetic Macular Edema; DME; Pharmacy

References

1. American Academy of Ophthalmology. Preferred Practice Pattern Age-Related Macular Degeneration. Updated periodically.
2. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.; URL: http://www.clinicalpharmacology.com. Updated periodically.
3. Lexi-Comp [database online]. Hudson, OH: Lexi-Comp, Inc.; URL: http://online.lexi.com/crlsql/servlet/crlonline. Updated periodically.
4. Lucentis (ranibizumab) [package insert] San Francisco, CA: Genentech Inc; Revised March 2018.
5. Micromedex [database online]. New York, NY: Thomson Reuters, Inc.; URL: http://www.thomsonhc.com/micromedex2/librarian/. Updated periodically.

Disclaimer	State and federal law, as well as contract language, including definitions and specific inclusions/exclusions, take precedence over clinical policy and must be considered first in determining eligibility for coverage. Coverage may also differ for our Medicare and/or Medicaid members based on any applicable Centers for Medicare & Medicaid Services (CMS) coverage statements including National Coverage Determinations (NCD), Local Medical Review Policies (LMRP) and/or Local Coverage Determinations. See the CMS website at http://www.cms.hhs.gov/. The member's health plan benefits in effect on the date services are rendered must be used. Clinical policy is not intended to pre-empt the judgment of the reviewing medical director or dictate to health care providers how to practice medicine. Health care providers are expected to exercise their medical judgment in rendering appropriate care. Clinical technology is constantly evolving, and we reserve the right to review and update this policy periodically.